Table 2:
Cohort pre-transplant characteristics, stratified by procedure type
| Single LTx (N=6599) | Bilateral LTx (N=8669) | p value | |
|---|---|---|---|
| RECIPIENT | |||
| AGE AT TRANSPLANT | <0.0001 | ||
| Median (5th-95th percentile), years | 59.0 (43.0 – 69.0) | 50.0 (22.0 – 66.0) | |
| GENDER | 0.8026 | ||
| Female | 3001 (45.5%) | 3960 (45.7%) | |
| ABO BLOOD GROUP | 0.1784 | ||
| A | 2707 (41.0%) | 3574 (41.2%) | |
| AB | 252 (3.81%) | 356 (4.11%) | |
| B | 689 (10.4%) | 980 (11.3%) | |
| O | 2950 (44.7%) | 3759 (43.4%) | |
| Missing | 1 (.%) | 0 (.%) | |
| PRIMARY DIAGNOSTIC INDICATION FOR LTX | <0.0001 | ||
| COPD, non-A1ATD | 3245 (49.2%) | 2225 (25.7%) | |
| IIP | 2238 (33.9%) | 1739 (20.1%) | |
| Cystic fibrosis | 7 (0.11%) | 2183 (25.2%) | |
| COPD, A1ATD | 356 (5.39%) | 470 (5.42%) | |
| ILD, non-IIP | 208 (3.15%) | 255 (2.94%) | |
| Primary pulmonary hypertension | 45 (0.68%) | 351 (4.05%) | |
| Sarcoidosis | 126 (1.90%) | 322 (3.71%) | |
| All other diagnoses | 374 (5.67%) | 1123 (13.0%) | |
| Missing | 0 (.%) | 1 (.%) | |
| ERA OF TRANSPLANT | <0.0001 | ||
| 1/1/1994 through 12/31/2002 | 2938 (44.5%) | 2236 (25.8%) | |
| 1/1/2003- 12/31/2011 | 3661 (55.5%) | 6433 (74.2%) | |
| ON LIFE IMMEDIATELY PRIOR TO LTx | <0.0001 | ||
| No | 6393 (97.6%) | 7869 (91.6%) | |
| Yes | 158 (2.39%) | 724 (8.35%) | |
| Missing | 48 (.%) | 76 (.%) | |
| MOST RECENT PRA PERCENT - CLASS 1 | 0.2039 | ||
| Median (5th-95th), % | 0.0 (0.0 – 18.0) | 0.0 (0.0 – 25.0) | |
| MOST RECENT PRA PERCENT - CLASS 2 | 0.8872 | ||
| Median (5th-95th), % | 0.0 (0.0 – 23.0) | 0.0 (0.0 – 18.0) | |
| DONOR | |||
| AGE | 0.6085 | ||
| Median (5th-95th), years | 30.0 (15.0 – 57.0) | 30.0 (15.0 – 57.0) | |
| GENDER | <0.0001 | ||
| Female | 2411 (36.5%) | 3596 (41.5%) | |
| Male | 4188 (63.5%) | 5073 (58.5%) | |
| ABO BLOOD GROUP | 0.0067 | ||
| A | 2404 (36.4%) | 3227 (37.2%) | |
| AB | 129 (1.96%) | 203 (2.34%) | |
| B | 649 (9.83%) | 954 (11.0%) | |
| O | 3417 (51.8%) | 4285 (49.4%) | |
| HISTORY OF HIGH RISK BEHAVIOR | 0.0325 | ||
| No | 2917 (44.2%) | 5364 (61.9%) | |
| Yes | 199 (3.01%) | 442 (5.09%) | |
| Missing | 3483 (52.8%) | 2863 (33.0%) | |
| ISCHEMIC TIME FOR LAST LUNG IMPLANTED | <0.0001 | ||
| Median (5th-95th), hours | 3.9 (2.0 – 6.3) | 5.4 (3.1 – 8.4) | |
| DONOR / RECIPIENT CMV STATUS | <0.0001 | ||
| Negative / Negative | 883 (13.4%) | 1544 (17.8%) | |
| Negative / Positive | 1557 (23.6%) | 1609 (18.6%) | |
| Positive / Negative (“mismatch”) | 1177 (17.8%) | 2001 (23.1%) | |
| Positive / Positive | 2391 (36.2%) | 2727 (31.5%) | |
| Missing | 591 (8.96%) | 788 (9.09%) | |
After excluding missing cases, P-values calculated using Wilcoxon rank sum test for continuous variables and Chi-square test for categorical variables. IIP limited to those with a diagnosis of “UIP/IPF” in the ISHLT Registry. Abbreviations: A1ATD, alpha-1-antitrypsin deficiency; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PRA, panel reactive antibody; UIP, usual interstitial pneumonitis.